North America: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
OhioHealth Settlement And White House Report Signal Broader Federal Focus On Restrictive Hospital Contracting
The proposed OhioHealth consent decree resolves DOJ antitrust allegations against OhioHealth but may be less an isolated resolution than the beginning of a broader enforcement trend. Filed just weeks after the DOJ brought a nearly identical suit against the NewYork-Presbyterian hospital system, and paired with a related White House economic analysis released within days of the settlement, the resolution marks a coordinated effort by the Trump administration to challenge dominant hospital systems over contracting practices that constrain health plan network design options.
United States Healthcare
CM
Crowell & Moring LLP
Article
What Do The Medicaid Community Engagement Requirements Mean For Medicaid Managed Care And Provider Operations?
On June 3, 2026, CMS issued an Interim Final Rule titled “Medicaid Program; Community Engagement Requirement for Certain Individuals” (Interim Final Rule) establishing federal parameters for state implementation of Medicaid community engagement (i.e., work reporting) requirements for certain populations. The Interim Final Rule implements provisions of the President’s One Big Beautiful Bill Act signed into law in July 2025 (OBBA).
United States Healthcare
M
Mintz
Article
Inflation Reduction Act Update: What’s Changing In Drug Pricing
The Inflation Reduction Act (IRA) continues to reshape the US drug‑pricing landscape as federal implementation accelerates and market responses evolve. In 2025, regulators advanced core IRA programs affecting Medicare negotiation, inflation rebates, and benefit redesign, while litigation, executive action, and agency rulemaking clarified, and in some cases expanded, the federal government’s role in pharmaceutical pricing and access.
United States Healthcare
M
Mintz
See more

Highlighted Content

Life Sciences, Biotechnology & Nanotechnology

See more

Healthcare

Article
OhioHealth Settlement And White House Report Signal Broader Federal Focus On Restrictive Hospital Contracting
The proposed OhioHealth consent decree resolves DOJ antitrust allegations against OhioHealth but may be less an isolated resolution than the beginning of a broader enforcement trend. Filed just weeks after the DOJ brought a nearly identical suit against the NewYork-Presbyterian hospital system, and paired with a related White House economic analysis released within days of the settlement, the resolution marks a coordinated effort by the Trump administration to challenge dominant hospital systems over contracting practices that constrain health plan network design options.
United States Healthcare
CM
Crowell & Moring LLP
Article
What Do The Medicaid Community Engagement Requirements Mean For Medicaid Managed Care And Provider Operations?
On June 3, 2026, CMS issued an Interim Final Rule titled “Medicaid Program; Community Engagement Requirement for Certain Individuals” (Interim Final Rule) establishing federal parameters for state implementation of Medicaid community engagement (i.e., work reporting) requirements for certain populations. The Interim Final Rule implements provisions of the President’s One Big Beautiful Bill Act signed into law in July 2025 (OBBA).
United States Healthcare
M
Mintz
See more

Food and Drugs Law

Article
Inflation Reduction Act Update: What’s Changing In Drug Pricing
The Inflation Reduction Act (IRA) continues to reshape the US drug‑pricing landscape as federal implementation accelerates and market responses evolve. In 2025, regulators advanced core IRA programs affecting Medicare negotiation, inflation rebates, and benefit redesign, while litigation, executive action, and agency rulemaking clarified, and in some cases expanded, the federal government’s role in pharmaceutical pricing and access.
United States Healthcare
M
Mintz
See more

Latest Videos

See more